Skip to main content
. 2024 Mar 6;14(1):38. doi: 10.1038/s41408-024-01024-8

Fig. 1. Overview of the study.

Fig. 1

A A plasma B-cell signature was defined to quantify the magnitude of malignancy of MM samples. The resulting plasma B malignancy (PBM) score is associated with the patient’s prognosis. B The PBM scores of CD138+ cells were found to be used for prognosis prediction, characterize the MM development and progression, and be correlated with the patient’s immune microenvironment and cytogenetic abnormalities. C The PB signature was incorporated into the prognostic model to improve prediction accuracy for better clinical application.